Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis

Immune thrombotic thrombocytopenic purpura (iTTP) is an acquired, fatal microangiopathy if untreated. Randomized controlled trials (RCTs) demonstrated faster time to response with addition of caplacizumab to standard of care (SOC). However, concerns about RCT selection bias and the high cost of capl...

Descripción completa

Detalles Bibliográficos
Autores principales: Djulbegovic, Mia, Tong, Jiayi, Xu, Alice, Yang, Joanna, Chen, Yong, Cuker, Adam, Pishko, Allyson M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196763/
https://www.ncbi.nlm.nih.gov/pubmed/36053773
http://dx.doi.org/10.1182/bloodadvances.2022008443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196763/
https://www.ncbi.nlm.nih.gov/pubmed/36053773
http://dx.doi.org/10.1182/bloodadvances.2022008443

Ejemplares similares